Popular weight-loss medications such as Ozempic and Wegovy may offer benefits beyond weight management, with early research suggesting they could help reduce cravings for alcohol and some addictive substances.
The drugs belong to a class known as GLP-1 receptor agonists, which were originally developed to treat type 2 diabetes. They mimic the naturally occurring GLP-1 hormone, helping regulate blood sugar, slow digestion and increase feelings of fullness.
Scientists are now investigating whether these medications may also affect the brain's reward system, which influences appetite, pleasure and addictive behaviour.
GLP-1 drugs and addiction
Research has found that people taking GLP-1 medications may consume less alcohol, while early animal studies have suggested the drugs could reduce the use of substances including cocaine, amphetamines, opioids and nicotine.
Researchers believe the potential effect may be linked to how GLP-1 medications interact with pathways in the brain involved in reward and motivation.
Cravings occur when the brain's reward system creates a strong desire to obtain and use a particular substance or consume certain foods.
When this system becomes excessively active, it can contribute to conditions including obesity, alcohol misuse and substance addiction.
More research needed
Despite the promising findings, experts caution that the evidence is still developing.
Much of the research into the potential anti-addiction effects of GLP-1 drugs remains in its early stages, particularly in humans.
Researchers say larger and longer-term clinical studies are needed to determine whether medications such as Ozempic and Wegovy could eventually be used as part of treatment for substance-use disorders.
For now, GLP-1 drugs remain primarily approved for conditions such as type 2 diabetes and weight management, depending on the specific medication and regulatory approval.
